Bayer Cash Flow from Investing Activities 2010-2024 | BAYRY

Bayer annual/quarterly cash flow from investing activities history and growth rate from 2010 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
  • Bayer cash flow from investing activities for the quarter ending December 31, 2024 was $0.177B, a 104.66% decline year-over-year.
  • Bayer cash flow from investing activities for the twelve months ending December 31, 2024 was $-0.367B, a 67.7% decline year-over-year.
  • Bayer annual cash flow from investing activities for 2024 was $0.177B, a 104.66% decline from 2023.
  • Bayer annual cash flow from investing activities for 2023 was $-3.806B, a 51.73% increase from 2022.
  • Bayer annual cash flow from investing activities for 2022 was $-2.509B, a 348% decline from 2021.
Bayer Annual Cash Flow Investing
(Millions of US $)
2024 $177
2023 $-3,806
2022 $-2,509
2021 $1,012
2020 $-4,653
2019 $-752
2018 $-40,334
2017 $-488
2016 $-9,660
2015 $-3,067
2014 $-20,656
2013 $-3,428
2012 $-1,052
2011 $-5,418
2010 $-3,206
2009 $-1,570
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $23.028B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $835.717B 67.80
Novo Nordisk (NVO) Denmark $406.526B 27.53
Johnson & Johnson (JNJ) United States $394.223B 16.39
AbbVie (ABBV) United States $360.274B 20.17
Roche Holding AG (RHHBY) Switzerland $264.748B 0.00
Merck (MRK) United States $230.880B 11.95
Novartis AG (NVS) Switzerland $223.246B 13.98
Pfizer (PFE) United States $151.025B 8.57
Sanofi (SNY) $136.409B 12.92
Innoviva (INVA) United States $1.132B 9.42